The effect of metformin on Anti-Mullerian hormone levels in obese wome
- Conditions
- polycystic ovarian syndrome.Polycystic ovarian syndrome
- Registration Number
- IRCT201107317165N1
- Lead Sponsor
- Vice Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 80
80 infertile patient aged 20-35 years with pcos will include in the study in ARASH hospital of medical science from August 2011 till August 2013.the study was approved by the ethic committee of Tehran university of medical sciences and informed consent will obtain from each woman. Patients who have 2 of 3 criteria are diagnosed as polycystic ovarian syndrome: oligo-and/or anovulation; clinical/or biochemical signs of hyperandrogenism; polycystic ovarian syndrome ovaries.
Exclusion criteria: congenital adrenal hyperplasia; Cushing syndrome; thyroid dysfunction; androgens secreting
Tumors; diabetes; hyperprolactinemia and pregnancy. All patients have Body Mass index greater than 27 kg/m and normal liver and renal function tests. None of the subjects in both groups receive OCP or drugs for ovulation induction on day 3 of menstrual cycle, after an overnight fasting.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Androgen levels in obese women with PCOs. Timepoint: at the beginning and after 6 months. Method of measurement: by laboratory kit from blood sample.
- Secondary Outcome Measures
Name Time Method SHBG levels in obese women with PCOs. Timepoint: at the beginning and after 6 months. Method of measurement: by laboratory kit from blood sample.